Local Study of Akatinol Memantine in VaD in Russia

Exclusion Criteria

• •Alzheimer's disease or secondary types of dementia.
• •Epilepsy, seizures, schizophrenia, other psychoses, bipolar disorder, alcoholism, drug abuse (including the history thereof).
• •Other clinically significant neurological or psychiatric disorders.
• •Severe depression (Hamilton score, HAM-D \> 18 points).
• •Severe, unstable or decompensated physical disease (including clinically significant laboratory abnormalities) potentially affecting the trial findings.
• •Contraindications to oral drug intake during the time period determined by the study protocol.
• •Known hypersensitivity to the investigational product or any of its ingredients.
• •Administration of nootropic, anti-dementia and typical antipsychotic drugs, tricyclic antidepressants, long-acting benzodiazepines, NMDA receptor antagonists (amantadine, ketamine, dextromethorphan) for 1 month before the enrollment and during the study.
• •For females: pregnancy and breastfeeding.
• •Evidence or suspicion that the patient might not comply with the study directive.
• •Any reason or contraindication which in the investigator's opinion precludes participation in the study.
• •Patient is direct relative of an employee of the study site or Merz Pharma LLC.
• •Previous participation in this clinical study.
• •Participation in another clinical trial within the last 12 weeks prior to screening or ongoing participation in a study.